Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Robalzotan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 20/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Robalzotan SCHEMBL4811762 | 1.00 | HTR1A (1.00) | HTR1ASLC6A4 | |
| SCHEMBL6820275 | 0.99 | HTR1A (0.98) | HTR1ASLC6A4 | |
| SCHEMBL6820286 | 0.99 | HTR1A (0.98) | HTR1ASLC6A4 | |
| Robalzotan SCHEMBL6315984 | 0.93 | HTR1A (0.87) | HTR1ASLC6A4 | |
| Robalzotan SCHEMBL31060340 | 0.89 | HTR1A (0.80) | HTR1ASLC6A4 | |
| SCHEMBL7616889 | 0.89 | HTR1A (0.80) | HTR1ASLC6A4 | |
| SCHEMBL7616883 | 0.89 | HTR1A (0.80) | HTR1ASLC6A4 | |
| SCHEMBL7619185 | 0.88 | HTR1A (0.78) | HTR1ASLC6A4 | |
| SCHEMBL7619191 | 0.88 | HTR1A (0.78) | HTR1ASLC6A4 | |
| SCHEMBL6823734 | 0.85 | HTR1A (0.73) | HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-11794009-B2 | Devices, systems and methods for treating urological and gastrointestinal disorders by electrical stimulation of the foot | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-24 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| US-20210370059-A1 | Devices, Systems and Methods for Treating Urological and Gastrointestinal Disorders by Electrical Stimulation of the Foot | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-12-02 | — | — | US | claimed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | claimed |
| US-6159972-A | Combination of a selective 5-HT1A antagonist and a selective ub. h5-HT.s1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | claimed |
| EP-1021183-A1 | A COMBINATION OF A SELECTIVE 5-HT 1A? ANTAGONIST AND A SELECTIVE h5-HT 1B? ANTAGONIST OR PARTIAL AGONIST | AstraZeneca AB (SE) | 2000-07-26 | — | — | EP | claimed |
| WO-2000015220-A1 | A NEW COMPOSITION | ASTRAZENECA AB (SE) | 2000-03-23 | — | — | WO | claimed |
| EP-0984952-A1 | A NEW SALT | Astra Aktiebolag (SE) | 2000-03-15 | — | — | EP | claimed |
| US-5962514-A | Combination of 5-HT uptake inhibitor with a selective 5-HT1A antagonist | ASTRA AKTIEBOLAG (SE) | 1999-10-05 | — | — | US | claimed |
| WO-1999013876-A1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | claimed |
| WO-1998054166-A1 | A NEW SALT | ASTRA AKTIEBOLAG (SE) | 1998-12-03 | — | — | WO | claimed |
| US-5616610-A | CENTRAL NERVOUS SYSTEM DISORDERS | ASTRA AKTIEBOLAG (SE) | 1997-04-01 | — | — | US | claimed |
| EP-0725779-A1 | NOVEL (R)-5-CARBAMOYL-8-FLUORO-3-N,N-DISUBSTITUTED-AMINO-3,4-DIHYDRO-2H-1-BENZOPYRANES | Astra Aktiebolag (SE) | 1996-08-14 | — | — | EP | claimed |
| WO-1995011891-A1 | NOVEL (R)-5-CARBAMOYL-8-FLUORO-3-N,N-DISUBSTITUTED-AMINO-3,4-DIHYDRO-2H-1-BENZOPYRANES | ASTRA AKTIEBOLAG (SE) | 1995-05-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | HTR1A 156/4885SLC6A4 1763/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR1A 4/4885SLC6A4 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.